<DOC>
	<DOCNO>NCT00489255</DOCNO>
	<brief_summary>The purpose study determine : . To assess efficacy Tigan® ( trimethobenzamide ) prevent nausea vomit initiate therapy Apokyn® ( apomorphine ) ii . To determine optimal duration continuation Tigan® follow initiation Apokyn® therapy iii . To assess safety Tigan® combination Apokyn® iv . To characterize pharmacokinetic ( PK ) profile apomorphine subject treat concomitantly without Tigan®</brief_summary>
	<brief_title>Safety/Efficacy Tigan® Control Nausea/Vomiting Experienced During Apokyn® Initiation Treatment</brief_title>
	<detailed_description>Initial randomization Tigan Placebo ( 3:1 ) phase withdrawal Tigan Placebo 4 8 week . Subjects complete 4 week Tigan re-randomized Tigan Placebo ( 2:1 ) patient complete 8 week Tigan re-randomized receive Tigan Placebo ( 1:1 ) . Subjects randomize Placebo previous 4 week assign continue Placebo remainder study .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Trimethobenzamide</mesh_term>
	<criteria>Subjects age 18 year Subjects advance Parkinson 's disease disabling hypomobility ( `` '' episode ) initiate Apokyn® intermittent subcutaneous injection Able swallow Tigan®/placebo capsule Subjects willing able comply schedule visit , treatment plan , laboratory test study procedure Women child bear potential must negative serum pregnancy test ( beta hCG ) prior receive study drug must use appropriate form contraception Willing able provide inform consent Hypersensitive apomorphine hydrochloride ingredient Apokyn® ( notably sodium metabisulfite ) Hypersensitive trimethobenzamide ingredient Tigan® Previous treatment Apokyn® Participation clinical trial within 14 day present trial Contraindications Apokyn® Tigan® Currently take , likely need take time course study , 5HT3 antagonist ( ondansetron , alosetron , granisetron , palonosetron dolasetron ) Malignant melanoma history previously treat malignant melanoma Pregnancy breast feed Receipt investigational ( i.e . unapproved ) medication within 30 day start present trial Any significant medical disorder , condition , concomitant medication psychiatric disorder accord DSMIV criterion would , opinion investigator , represent hazard subject prevent subject complete trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Anti-emetic</keyword>
	<keyword>Nausea</keyword>
	<keyword>Vomiting</keyword>
</DOC>